Neutralizing antibodies against two HIV-1 strains in consecutively collected serum samples: cross neutralization and association to HIV-1 related disease.

97 sera collected during a 10-year period from 10 HIV-1 infected individuals were tested for neutralizing capacity against a virus isolate FICPH-22 obtained from a Danish AIDS patient, and the laboratory strain HTLV-IIIB. Three patterns of serum neutralizing activity were demonstrated: (a) patients developing high neutralizing activity against both HIV strains; (b) patients developing high neutralizing activity against the Danish virus isolate; and (c) patients developing only low titers of neutralizing antibodies (NA) against both HIV strains. The HTLV-IIIB strain was less sensitive to serum neutralization than the FICPH-22 isolate and the appearance of NA against HTLV-IIIB was typically lacking several years behind that against FICPH-22 indicating a broadening of the NA response over time. No difference in clinical outcome was observed comparing patients reaching high titers of NA and patients with low titers. Development of AIDS among patients reaching high titers of NA was preceded by a decline in NA titers, indicating an association of high titers of NA with the healthy carrier state and of declining or low titers of NA with disease progression. The majority of the neutralizing activity was mediated by IgG, but some neutralizing activity was demonstrated in the IgG depleted serum, indicating the presence of additional neutralizing substances in serum.

[1]  D. Katzenstein,et al.  Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans. , 1990, Journal of acquired immune deficiency syndromes.

[2]  L. Arthur,et al.  Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120). , 1989, Vaccine.

[3]  J. Nielsen,et al.  HIV neutralizing antibodies: development and association with HIV related disease. , 1989, Scandinavian journal of infectious diseases.

[4]  L. Arthur,et al.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies , 1988, Journal of virology.

[5]  J. Goudsmit,et al.  Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. , 1988, Vaccine.

[6]  C. Debouck,et al.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Cheng‐Mayer,et al.  Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Rubinstein,et al.  Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. , 1987, The Journal of infectious diseases.

[9]  L. Arthur,et al.  Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Robert-Guroff,et al.  HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia. , 1987, Journal of immunology.

[11]  L. Epstein,et al.  Relationship between HTLV-III Neutralizing Antibody and Clinical Status of Pediatric Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex Cases , 1987, Pediatric Research.

[12]  C. Pedersen,et al.  The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. , 1987, AIDS.

[13]  I. Bygbjerg,et al.  DETECTION OF HIV ANTIGENS IN ELUATES FROM WHOLE BLOOD COLLECTED ON FILTERPAPER , 1987, The Lancet.

[14]  R. Tedder,et al.  HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN TWO COHORTS OF HOMOSEXUAL MEN: NEUTRALISING SERA AND ASSOCIATION OF ANTI-GAG ANTIBODY WITH PROGNOSIS , 1987, The Lancet.

[15]  J. Nielsen,et al.  Antibody to HIV in patients with acute hepatitis B in the period 1975-1984. , 1987, Scandinavian journal of infectious diseases.

[16]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[17]  R. Gallo,et al.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Grunnet,et al.  HTLV‐III Antibody Testing in Three Danish Blood Banks , 1986, Vox sanguinis.

[19]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[20]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[21]  D. Francis,et al.  Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). , 1985, Journal of immunological methods.

[22]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[23]  S. Maddison,et al.  Amoebic gel-diffusion precipitin-test. Clinical evaluation in acute amoebic dysentery. , 1966, Lancet.

[24]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .